Paragon Bioservices has plans to expand to new space over the next two years to help companies develop and manufacture biopharmaceuticals.
Researchers with the Johns Hopkins University School of Medicine developed a new blood test able to screen for eight types of cancers.
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an agreement with FUJIFILM Diosynth Biotechnologies (FUJIFILM) for the manufacture of REGENXBIO’s lead product candidates, including RGX-314 and RGX-501, which will support late-stage clinical development and early commercialization. This partnership builds on the foundation of REGENXBIO’s internal manufacturing and process development capabilities.
New York City is doubling down on its long-discussed, never-realized dream of building a biotech hub to rival South San Francisco and Boston. The latest iteration of the dream comes backed by a $500 million financing package and a goal to quadruple the amount of R&D space in the city.
After nearly a year, venture capitalists nabbed their first U.S. acquisition for more than a billion dollars. And it wasn’t a tech startup. Nor was it a company on the list of known unicorns. And it had nothing to do with blockchain.
Accelerate Baltimore™ is an initiative of the ETC (Emerging Technology Centers), Baltimore’s award winning incubator, and The Abell Foundation. In its first six years, we have invested $1,025,000 in 34 companies. We are now in our seventh year with 6 innovative technology startup companies who are working to accelerate their ideas to market.
Our goal is to close the gap between innovative ideas and getting to market by providing seed capital, resources, mentors, potential partners and a collaborative community. Accelerate Baltimore runs once a year, will you be ready for our next cohort?
Paragon Bioservices (Paragon), the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces the expansion of a new process development and cGMP manufacturing facility located conveniently near Baltimore/Washington International Thurgood Marshall (BWI) Airport. Growing need for broad gene therapy manufacturing capacity from its current and future client base is driving the company’s investment in this new facility, which the company expects will include commercial manufacturing capabilities in 18 to 24 months.
Analysts had forecast a blockbuster year for life science mergers and acquisitions as the lower tax rate for repatriated cash kicks-in and Big Pharma continues its hunt for late-stage assets.
The Association of the British Pharmaceutical Industry has released a report suggesting that pharma companies investing in emerging start-ups is now a key source of capital for biotech innovation in the UK.
Maryland Senate President Thomas V. Mike Miller Jr. (D-Calvert) and Democrats from Montgomery County are rallying around Republican Gov. Larry Hogan’s $5 billion incentive package to lure Amazon.com and a 50,000-person headquarters to the Washington suburb, but it remains to be seen whether the rest of the Democratic-majority legislature will support the package.